See more : Fourth Wave Energy, Inc. (FWAV) Income Statement Analysis – Financial Results
Complete financial analysis of Mereo BioPharma Group plc (MREO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mereo BioPharma Group plc, a leading company in the Biotechnology industry within the Healthcare sector.
- MFC-Nichada Thani Property Fund 2 (MNIT.BK) Income Statement Analysis – Financial Results
- G.M. Breweries Limited (GMBREW.NS) Income Statement Analysis – Financial Results
- Guangdong Greenway Technology Co., Ltd. (688345.SS) Income Statement Analysis – Financial Results
- Felix Gold Limited (FXG.AX) Income Statement Analysis – Financial Results
- Wine’s Link International Holdings Limited (8509.HK) Income Statement Analysis – Financial Results
Mereo BioPharma Group plc (MREO)
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.00M | 1.51M | 36.46M | 393.00K | -122.00K | 0.00 | -3.29M | 0.00 |
| Cost of Revenue | 2.57M | 936.00K | 17.91M | 16.35M | 23.61M | 22.70M | 34.61M | 24.56M |
| Gross Profit | 7.43M | 571.00K | 18.56M | -15.95M | -23.73M | -22.70M | -37.89M | -24.56M |
| Gross Profit Ratio | 74.26% | 37.89% | 50.89% | -4,059.54% | 19,450.82% | 0.00% | 1,153.38% | 0.00% |
| Research & Development | 17.42M | 24.96M | 23.56M | -16.35M | -23.61M | 22.70M | 34.61M | 24.56M |
| General & Administrative | 18.42M | 19.54M | 15.93M | 21.22M | 15.91M | 12.50M | 10.70M | 11.62M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.42M | 19.54M | 15.93M | 21.22M | 15.91M | 12.50M | 10.70M | 11.62M |
| Other Expenses | 0.00 | 811.00K | 0.00 | 0.00 | 0.00 | 0.00 | -293.33K | 0.00 |
| Operating Expenses | 35.84M | 44.51M | 39.49M | 21.22M | 15.91M | 12.50M | 10.70M | 11.62M |
| Cost & Expenses | 38.42M | 43.57M | 57.40M | 37.57M | 39.52M | 35.21M | 45.30M | 36.18M |
| Interest Income | 2.13M | 696.00K | 1.00K | 44.00K | 377.00K | 306.83K | 826.86K | 195.14K |
| Interest Expense | 2.88M | 3.36M | 4.00M | 6.38M | 3.50M | 2.36M | 1.09M | 179.77K |
| Depreciation & Amortization | 1.06M | 1.51M | 866.47K | 44.00K | 1.95M | 37.80K | 36.08K | 32.94K |
| EBITDA | -26.06M | -42.06M | -5.00M | -37.53M | -37.56M | -34.86M | -44.44M | -38.41M |
| EBITDA Ratio | -260.56% | -2,791.11% | -55.71% | -9,548.35% | 30,789.34% | 0.00% | 1,352.72% | 0.00% |
| Operating Income | -28.42M | -43.57M | -20.94M | -37.57M | -39.52M | -35.21M | -45.30M | -36.18M |
| Operating Income Ratio | -284.16% | -2,891.11% | -57.42% | -9,559.54% | 32,390.98% | 0.00% | 1,378.99% | 0.00% |
| Total Other Income/Expenses | -1.58M | 7.48M | 40.16M | -129.27M | -1.60M | -2.10M | -1.65M | 2.46M |
| Income Before Tax | -30.00M | -36.09M | 14.24M | -166.45M | -41.12M | -37.31M | -46.95M | -33.72M |
| Income Before Tax Ratio | -299.98% | -2,395.02% | 39.05% | -42,353.69% | 33,703.28% | 0.00% | 1,429.13% | 0.00% |
| Income Tax Expense | -532.00K | -1.90M | 1.52M | -2.82M | -6.27M | -5.28M | -8.15M | -5.33M |
| Net Income | -29.47M | -34.20M | 12.73M | -163.63M | -34.84M | -32.03M | -38.80M | -28.39M |
| Net Income Ratio | -294.66% | -2,269.14% | 34.90% | -41,635.62% | 28,560.66% | 0.00% | 1,180.99% | 0.00% |
| EPS | -0.04 | -0.06 | 0.02 | -0.48 | -0.39 | -0.45 | -0.56 | -0.63 |
| EPS Diluted | -0.04 | -0.06 | 0.02 | -0.48 | -0.39 | -0.45 | -0.56 | -0.63 |
| Weighted Avg Shares Out | 659.45M | 603.20M | 527.82M | 337.72M | 89.34M | 71.14M | 69.01M | 44.79M |
| Weighted Avg Shares Out (Dil) | 659.45M | 603.20M | 555.28M | 338.95M | 89.42M | 71.14M | 69.01M | 44.79M |
What Makes MEREO BIOPHARMA (MREO) a Strong Momentum Stock: Buy Now?
4 Hot Penny Stocks To Watch With News This Week
MEREO BIOPHARMA (MREO) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside
How to Find Penny Stocks to Buy in Summer 2022
How to Make a Penny Stocks Watchlist in July 2022
Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout
Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List
Why Mereo BioPharma Shares Are Jumping Today
AstraZeneca weighing bid for Mereo BioPharma: report
Source: https://incomestatements.info
Category: Stock Reports